Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Galimedix Therapeutics has commenced a pivotal Phase 2 study investigating the efficacy of GAL-101 eye drops in treating geographic atrophy, a severe form of dry age-related macular degeneration (AMD). This trial aims to enroll 110 patients across the US, Europe, and Israel, following discussions with the FDA and EU authorities and backed by leading retina experts. The study will assess the eye drops' ability to slow or stop the progression of geographic atrophy.

This advancement comes after a successful Phase 1 trial for both topical and oral formulations of GAL-101, showcasing its safety and tolerability. GAL-101 targets misfolded Aβ monomers to prevent harmful aggregate formation, potentially treating AMD, glaucoma, and Alzheimer's disease. It holds the promise of neuroprotection, having shown efficacy in protecting retinal cells in pre-clinical trials.

The trial is funded by Théa Open Innovation, underscoring Galimedix's commitment to developing innovative treatments for serious eye diseases.